Log In

 

Company Name : Boehringer Ingelheim

Wednesday, November 8, 2017 8:35PM IST (3:05PM GMT)

(BW)(BOEHRINGER-INGELHEIM)

Boehringer Ingelheim and MiNA Therapeutics to Develop Novel Treatment Approaches for Fibrotic Liver Diseases


Collaboration and licensing agreement focused on investigating up to three targets and has a potential transactional value of up to EUR 307 million, excluding royalties; Expands Boehringer Ingelheim’s comprehensive R&D programme in non-alcoholic steatohepatitis (NASH) and fibrotic liver disease with innovative novel treatment modalities; Leverages MiNA’s leading expertise in RNA activation therapeutics, evaluating the platform technology’s potential to prevent disease progression by restoring normal cell and target organ function


Ingelheim, Germany & London, United Kingdom

Boehringer Ingelheim and MiNA Therapeutics (“MiNA”), a pioneer in RNA activation therapeutics, today announced that they have signed a collaboration and licensing agreement focused on the development of novel compounds to treat fibrotic liver diseases such as NASH, based on MiNA’s small activating RNA (“saRNA”) therapeutics platform. The new partnership underscores Boehringer Ingelheim’s commitment to advancing innovative new treatment approaches and furthering its comprehensive clinical offerings in cardiometabolic diseases. It combines MiNA’s leading expertise in the development of saRNAs with Boehringer Ingelheim’s experience in bringing first-in-class breakthrough treatments to patients with cardiometabolic disease.

 

NASH is a major cause of liver fibrosis and cirrhosis and an area of high unmet medical need. It has an especially high prevalence among obese and diabetic patients and currently there are no treatments available. NASH is expected to become the most common cause of advanced liver disorders eventually necessitating liver transplantation in the coming decades.

 

saRNAs have been demonstrated to activate transcription of specific genes resulting in upregulation of proteins with therapeutic potential. In the new collaboration, Boehringer Ingelheim and MiNA aim to identify targets to restore metabolic functionality of hepatocytes and prevent fibrotic tissue formation in patients with NASH. It will enable Boehringer Ingelheim to rapidly design, profile and develop novel compounds, potentially also creating opportunities for combination with Boehringer Ingelheim’s other NASH-pipeline assets.

 

“This collaboration is a recognition of our platform and expertise in liver-based diseases as well as validation from an established pharmaceutical leader in what has been an exciting year for the company,” said Robert Habib, CEO of MiNA.

 

“This new collaboration is another sign of our ongoing commitment to patients with cardio-metabolic diseases, including NASH,” said Clive R. Wood, Ph.D., Corporate Senior Vice President Discovery Research at Boehringer Ingelheim. “It will combine MiNA’s pioneering work with saRNAs with our expertise in biopharmaceutical research and development,” added Wood.

 

Boehringer Ingelheim has a long history of excellence in the discovery and development of medicines for cardiometabolic disease patients. It has established a broad portfolio of marketed products for thromboembolic diseases, type 2 diabetes, acute myocardial infarction, hypertension and cardio-renal risk reduction. The cardiometabolic diseases pipeline extends beyond type 2 diabetes and anticoagulation with a focus on innovative drugs for the treatment of the devastating consequences of diabetes as well as contributing factors like obesity.

 

Under the terms of the agreement, MiNA will receive an upfront payment and committed research funding as well as potential research, development and regulatory milestone payments totalling up to EUR 307 million. In addition, MiNA is entitled to up to double-digit royalties on sales of selected products resulting from the partnership. No further financial details have been disclosed.

 

In this agreement, MiNA was advised by Ferghana Partners and Taylor Wessing LLP.

 

Please click on the link below for ‘Notes to Editors’:
http://www.boehringer-ingelheim.com/press-release/collaboration-mina-develop-nash-treatments

 

 

 

 


Click here for Media Contact Details
CONTACTS :

Contact for MiNA Therapeutics:
Dr. Stephanie May
MacDougall Biomedical Communications
P: +49 89 2424 3494 :: M: +49 175 571 1562
E-Mail: smay@macbiocom.com
or
Contacts for Boehringer Ingelheim:
Boehringer Ingelheim

Dr. Reinhard Malin
Head of Communications Innovation Unit
Boehringer Ingelheim GmbH
P: +49 6132 77-90815 :: M: + 49 151 150 20 690
reinhard.malin@boehringer-ingelheim.com
or
Linda Ruckel
Associate Director, Media and Corporate Reputation
Boehringer Ingelheim Pharmaceuticals, Inc.
Ridgefield, Connecticut
P: +1 203 791-6672 :: M: +1 203-957 5114
linda.ruckel@boehringer-ingelheim.com


More News from Boehringer Ingelheim

18/02/2018 1:59PM

Systemic Sclerosis World Congress: Inspirational Patient Stories Reveal the Challenging Realities of Living with Devastating Rare Disease

'More Than Scleroderma: The Inside Story' provides real-life stories and education about the life-threatening disease New and truly inspiring patient stories are revealed Help raise awareness of this ...

04/01/2018 6:21PM

Boehringer Ingelheim Demonstrates Continuous Commitment to Its Venture Fund and Fostering Innovation by More than Doubling Funding to 250 M€

Boehringer Ingelheim announced an increase in funding for its corporate venture fund, known as the Boehringer Ingelheim Venture Fund (BIVF), from EUR 100 to 250 million. The additional funds will be used to invest in ...

11/12/2017 7:30PM

Boehringer Ingelheim Marks Great Progress in Immuno-oncology Research Partnerships in 2017

2017 marks a year of significant advancement for Boehringer Ingelheim as it secured a range of external partnerships with the goal of transforming the lives of patients and winning the fight against cancer. External ...

Similar News

20/02/2018 1:15PM

Herbalife Nutrition India Launches Strawberry Flavour of Dinoshake Nutritional Children's Drink Mix

Herbalife Nutrition, a global nutritional company, announced it is doubling the tastes available for Dinoshake Nutritional Children’s Drink Mix in Indai, adding Strawberry flavour to accompany the delicious Dinoshake ...

No Image

20/02/2018 1:06PM

बेस्ट क्योर फाउंडेशन (बीसीएफ) और टीमबेस्ट कंपनीज अंतरराष्ट्रीय स्तर पर मुनाफा न कमाने वाली/गैरसरकारी बेस्ट क्योर हेल्थ सिस्टम और बेस्ट क्योर इंश्योरेंस की शुरुआत कर रहे हैं ताकि 10 ट्रिलियन अमेरिकी डॉलर से ज्यादा की अंतरराष्ट्रीय हेल्थकेयर डिलीवरी सिस्टम को बहुत बेहतर और कम महंगा बनाया जा सके

कृष्णन सुथांथिरण ने 2007 में बेस्ट केयर फाउंडेशन (मुनाफ न कमाने वाले एक गैरसरकारी संगठन) की स्थापना की ताकि उच्च गुणवत्ता वाले हेल्थकेयर और उच्च शिक्षा को किफायती बनाया जा सके और अंतरराष्ट्रीय स्तर पर हर ...